Evidence map›Paper›PMID 32354987›Full record

Trial reportJournal of the American Society of Nephrology : JASN2020

Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.

Meg J Jardine, Zien Zhou, Kenneth W Mahaffey, Megumi Oshima, Rajiv Agarwal, George Bakris, Harpreet S Bajaj, Scott Bull, Christopher P Cannon, David M Charytan and 15 more

Registry-linked trialOpen access · hybridAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02065791. Cited by 89 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 11 pooled it
18.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02065791 phase3completed

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

Ran2014Enrolled4,401Registered outcomes8Posted comparisons8ConditionsDiabetes Mellitus, Type 2, Diabetic NephropathyArmsCanagliflozin, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 11 syntheses or guidelines pooled it, 172 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 17 institutions in 7 countries.

Meg J JardineThe George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia mjardine@georgeinstitute.org.au.
Zien ZhouThe George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.
Kenneth W MahaffeyDepartment of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, California.
Megumi OshimaThe George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-4108-5229
Rajiv AgarwalIndiana University School of Medicine and Veterans Affairs Medical Center, Indianapolis, Indiana.
George BakrisDepartment of Medicine, University of Chicago Medicine, Chicago, Illinois.ORCID 0000-0003-1183-1267
Harpreet S BajajLMC Healthcare, Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada.ORCID 0000-0002-1461-1465
Scott BullJanssen Research & Development, LLC, Raritan, New Jersey.
Christopher P CannonCardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
David M CharytanBaim Institute for Clinical Research, Boston, Massachusetts.
Dick de ZeeuwDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Gian Luca Di TannaThe George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-5470-3567
Tom GreeneDivision of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah.
Hiddo J L HeerspinkThe George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.
Adeera LevinDivision of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.
Bruce NealThe George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.
Carol PollockKolling Institute of Medical Research, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Rose QiuJanssen Research & Development, LLC, Raritan, New Jersey.
Tao SunJanssen Research & Development, LLC, Raritan, New Jersey.
David C WheelerThe George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.
Hong ZhangRenal Division, Peking University First Hospital, Beijing, China.
Bernard ZinmanLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Norman RosenthalJanssen Research & Development, LLC, Raritan, New Jersey.
Vlado PerkovicThe George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.
CREDENCE Study Investigators
Janssen (United States) · USMount Sinai Hospital · CAThe University of Sydney · AUUniversity Medical Center Groningen · NLUNSW Sydney · AUBrigham and Women's Hospital · USConcord Repatriation General Hospital · AUIndiana University School of MedicineKanazawa University · JPNYU Langone Health · USPeking University · CNRoyal North Shore Hospital · AUShanghai Jiao Tong University · CNStanford Medicine · USUniversity of British Columbia · CAUniversity of Chicago · USUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCanagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by initial estimated glomerular filtration rate (eGFR).

methodsCREDENCE randomly assigned 4401 participants with an eGFR of 30 to <90 ml/min per 1.73 m

resultsAt screening, 1313 (30%), 1279 (29%), and 1809 (41%) participants had an eGFR of 30 to <45, 45 to <60, and 60 to <90 ml/min per 1.73 m

conclusionsCanagliflozin safely reduced the risk of renal and cardiovascular events, with consistent results across eGFR subgroups, including the subgroup initiating treatment with an eGFR of 30 to <45 ml/min per 1.73 m CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE), NCT02065791.

Indexed as

AdultAgedAlbuminuriaCanagliflozinCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic NephropathiesDouble-Blind MethodFemaleHumansKidneyKidney Tubules, ProximalMaleMiddle AgedRiskSodium-Glucose Transporter 2 InhibitorsCanagliflozinSodium-Glucose Transporter 2 Inhibitorscanagliflozinchronic kidney diseasediabetesend-stage kidney diseaseSGLT2 inhibitor

Identifiers

PMID32354987
PMCPMC7217416
OpenAlexW3022616650

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.